How where and how much antigen shown to immune cells shapes helper T cell behavior
Potent Signal 1 as a noncanonical Signal 3: antigen location, and peptide:MHCII complex density and half-life as drivers of CD4+ T cell differentiation
['FUNDING_R21'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11235946
This project looks at how the location, amount, and lifespan of tiny pieces of germs presented to immune cells change how helper (CD4+) T cells behave, which matters for infections and autoimmune diseases.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S HOSP OF PHILADELPHIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11235946 on ClinicalTrials.gov |
What this research studies
Researchers will compare antigens that come from outside a cell versus those made inside antigen-presenting cells and measure how many peptide:MHCII complexes form and how long they persist. They will track how those differences influence whether CD4+ T cells become inflammatory, regulatory, or other functional types using influenza-derived peptides as a model. The work uses laboratory experiments with cells and controlled animal models to mimic realistic antigen presentation. The goal is to clarify how the strength and location of 'Signal 1' can itself direct helper T cell fate.
Who could benefit from this research
Good fit: People with autoimmune conditions or those at risk for immune-related problems are the most relevant group for the findings, although this R21 is preclinical and not likely to enroll patients directly.
Not a fit: Patients looking for immediate new treatments should not expect direct benefit from this lab-focused project because it focuses on basic immune mechanisms rather than clinical care.
Why it matters
Potential benefit: If successful, this work could inform vaccine design and immune therapies that steer helper T cells away from harmful autoimmune responses and toward protective immunity.
How similar studies have performed: Prior laboratory studies have shown that antigen dose can influence T cell outcomes but gave mixed results using purified peptides, so applying physiological antigen presentation is a relatively novel extension.
Where this research is happening
PHILADELPHIA, UNITED STATES
- CHILDREN'S HOSP OF PHILADELPHIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EISENLOHR, LAURENCE CRANE — CHILDREN'S HOSP OF PHILADELPHIA
- Study coordinator: EISENLOHR, LAURENCE CRANE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases